The study, published in Frontiers in Cardiovascular Medicine, reveals that NPAS2, a core component of the molecular clock, is dramatically depleted in the diabetic heart and loses its characteristic 24-hour oscillation. When the researchers deleted the Npas2 gene specifically in cardiomyocytes, diabetic mice fared far worse, developing more severe heart dysfunction, enlarged and scarred heart tissue, and dangerous fat accumulation. Conversely, boosting NPAS2 levels with a targeted gene therapy vector restored cardiac function and metabolic balance, pointing to a previously unrecognized pathway that links the body’s internal clock to the heart’s energy supply.

To understand why this matters, it helps to consider how the heart fuels itself. Under normal conditions, the heart derives roughly 60 to 70 percent of its ATP from fatty acid oxidation, with the remainder coming from glucose. In diabetes, this balance tips sharply toward fat metabolism, a shift that produces lipotoxic byproducts, overwhelms the mitochondria, and generates damaging reactive oxygen species. Central to healthy glucose oxidation is pyruvate dehydrogenase, or PDH, the enzyme that converts pyruvate from glycolysis into acetyl-CoA, the molecule that feeds the tricarboxylic acid cycle. PDH activity is markedly suppressed in the diabetic heart, and restoring it has long been considered a promising therapeutic strategy.

The Xi’an team, led by Wenjiao Li, Bin Han, Di Zhu, Lixia Luan, and Xuyun Dang, began by tracking NPAS2 expression in two independent mouse models of type 2 diabetes. Measuring mRNA levels at six-hour intervals across a full day, they found that diabetic mice showed significantly reduced NPAS2 in the myocardium along with a flattened circadian rhythm. Protein levels measured at the light-dark transition points confirmed the depletion, and immunohistochemistry revealed that the decline began as early as eight weeks of age and worsened as the animals aged, suggesting an early and sustained breakdown of the heart’s internal clock.

To test whether this loss was merely a bystander effect or an active contributor to disease, the researchers generated mice whose Npas2 gene could be deleted specifically in cardiomyocytes using a tamoxifen-inducible Cre system. When these knockout animals were placed on a high-fat diet and given streptozotocin to induce diabetes, their hearts deteriorated dramatically compared to diabetic controls. Echocardiography at sixteen weeks showed reduced ejection fraction and fractional shortening, along with thickening of the interventricular septum. Staining revealed enlarged cardiomyocytes and extensive interstitial fibrosis. Biochemical analysis showed elevated triglycerides and free fatty acids in the heart tissue, and even systemic glucose tolerance was impaired, indicating that the loss of a single clock gene in heart muscle cells reverberates through whole-body metabolism.

The cellular mechanism came into focus through experiments on H9c2 cardiomyocytes exposed to a high-glucose, high-fat cocktail that mimics the diabetic environment. Using Seahorse extracellular flux analysis, the team showed that silencing NPAS2 reduced spare respiratory capacity, maximal respiration, and ATP production, compounding the damage caused by the diabetic-like conditions. Flow cytometry revealed increased apoptosis, and metabolite measurements showed accumulating triglycerides, free fatty acids, lactate, and pyruvate, a signature of blocked pyruvate entry into mitochondrial oxidation. Crucially, PDH activity dropped consistently whenever NPAS2 was knocked down, identifying the enzyme as a likely downstream target.

The reverse experiment proved equally compelling. When the researchers overexpressed NPAS2 using an adenoviral vector, the high-glucose, high-fat stress no longer suppressed mitochondrial respiration, and apoptosis was markedly reduced. Intracellular lipids fell, pyruvate and lactate levels declined, and PDH activity rose. The team then performed a decisive set of rescue experiments: overexpressing PDH largely rescued the damage caused by NPAS2 knockdown, while silencing PDH abolished the protective effects of NPAS2 overexpression. Measurements of malondialdehyde, a marker of oxidative stress, followed the same pattern, confirming that the NPAS2-PDH axis governs not only energy production but also the redox balance of the cell.

The translational payoff came in vivo. The researchers packaged NPAS2 into adeno-associated virus serotype 9 under a cardiac-specific troponin promoter and injected it into the tail veins of diabetic mice, including both wild-type animals and the cardiomyocyte-specific knockouts. Two weeks later, echocardiography showed significantly improved ejection fraction and fractional shortening, along with reduced septal thickening, in both genotypes. Histology confirmed less hypertrophy and fibrosis, cardiac triglyceride and free fatty acid content fell, and glucose tolerance tests showed flatter blood glucose excursions. Notably, the therapy worked even in mice genetically lacking NPAS2 in their heart cells, demonstrating that restoring the protein can overcome an established deficiency rather than merely preventing one.

The findings fit into a growing body of evidence that circadian biology is deeply intertwined with metabolism. Previous work has shown that deleting the clock gene Bmal1 in skeletal muscle impairs insulin-stimulated glucose uptake and reduces PDH activity, and that disrupted circadian oscillations in type 2 diabetes are linked to altered rhythmic mitochondrial metabolism in muscle. NPAS2 itself has been implicated in hepatic lipid homeostasis, blood pressure regulation, and protection against ischemia-reperfusion injury, but its role in the diabetic heart had never been systematically explored. The new study extends the concept of clock-controlled metabolism to the myocardium and identifies a specific molecular bridge, the NPAS2-PDH axis, that could be targeted pharmacologically or genetically.

Significant hurdles remain before this discovery reaches the clinic. The authors acknowledge that the precise mechanism by which NPAS2 regulates PDH, whether through direct transcriptional control or indirectly via regulators such as pyruvate dehydrogenase kinase 4, is still unresolved. The H9c2 cell line, while useful, does not fully recapitulate adult primary cardiomyocytes, and the long-term safety and efficacy of AAV9-mediated gene delivery in humans remain open questions. Diastolic function, an important dimension of diabetic cardiomyopathy, also warrants closer study. Still, the demonstration that a single circadian transcription factor can protect the diabetic heart by preserving mitochondrial glucose oxidation offers a genuinely new therapeutic direction, one that treats the disease not as a simple consequence of high blood sugar but as a failure of the heart’s internal timing system to keep its metabolic engines running on schedule.

Subject of Research: Role of the circadian clock gene NPAS2 and pyruvate dehydrogenase activity in diabetic cardiomyopathy

Article Title: NPAS2 attenuates diabetic cardiomyopathy by preserving pyruvate dehydrogenase activity and mitochondrial metabolic homeostasis

Article References: Li, W., Han, B., Zhu, D., Luan, L., & Dang, X. (2026). NPAS2 attenuates diabetic cardiomyopathy by preserving pyruvate dehydrogenase activity and mitochondrial metabolic homeostasis. Frontiers in Cardiovascular Medicine, 13, Article 1980726. https://doi.org/10.3389/fcvm.2026.1980726

Image Credits: AI Generated

DOI: 10.3389/fcvm.2026.1980726

Keywords: NPAS2, diabetic cardiomyopathy, circadian clock, pyruvate dehydrogenase, mitochondrial metabolism, glucose oxidation, AAV9 gene therapy, cardiac fibrosis, lipotoxicity, H9c2 cardiomyocytes, metabolic flexibility, oxidative stress

The enzyme at the heart of the study, abbreviated PaeASD, belongs to a family of proteins that rely on pyrroloquinoline quinone, or PQQ, a redox cofactor that allows certain enzymes to oxidize sugars without needing the more familiar nicotinamide cofactors. PaeASD catalyzes the oxidation of aldose sugars such as glucose, and it does so with a remarkable tolerance for heat and an unusually broad pH range. These properties make it an attractive candidate for biosensors and biofuel cells, where an enzyme is immobilized on an electrode to convert chemical energy from a sugar directly into electrical current. In principle, an enzyme that survives repeated heating and extreme acidity or alkalinity should be ideal for devices that must keep working for months or years in the field.

There was, however, a catch. When the researchers previously immobilized the wild-type PaeASD on an electrode, the resulting device produced disappointingly little current. The culprit was not instability but speed: the enzyme’s catalytic activity was simply too low to drive a useful flow of electrons. In earlier work, the team turned to directed evolution, a laboratory technique that mimics natural selection by introducing random mutations and screening for improved variants. That effort yielded a double mutant carrying two substitutions, R64Q and D350N, in which the arginine at position 64 is replaced by glutamine and the aspartate at position 350 is replaced by asparagine. The engineered enzyme showed a maximum reaction velocity 2.4 times higher than the original protein and, even more strikingly, a Michaelis constant for glucose 3.8 times lower, meaning the mutant binds its sugar substrate far more tightly.

What those numbers meant at the atomic level remained a mystery until now. To solve it, the team crystallized the double mutant in two states: one with the PQQ cofactor absent and one with PQQ bound at the active site. X-ray diffraction data collected at the Photon Factory synchrotron facility in Japan revealed the three-dimensional architecture of the enzyme at high resolution, allowing the researchers to compare the mutant structures with the previously determined wild-type structure and pinpoint exactly what the two mutations had changed.

The most dramatic difference involved a loop near the PQQ-binding site. In the mutant enzyme, the loop spanning residues N350 through R352 shifts noticeably away from the cofactor. This movement matters because of what sits at the end of that loop: arginine 352, a bulky, positively charged amino acid whose long side chain juts into the active site. In the wild-type enzyme, the researchers’ glucose-binding model showed that this arginine side chain is wedged directly between two critical chemical groups, the carboxyl group at position C2 of the PQQ cofactor and the hydroxyl group at position C3 of the glucose molecule. In effect, the arginine acts as a physical barrier, obstructing the sugar from settling into its proper catalytic position. In the mutant, that barrier simply is not there, because the loop has moved the arginine out of the way.

The structural comparison also revealed a second, independent effect tied to the D350N mutation. Calcium ions play an essential structural and catalytic role in PQQ-dependent enzymes, and the crystal structures showed that the mutant enzyme retained a calcium ion at its active site even in the PQQ-unbound form, whereas the wild-type enzyme did not. This observation suggested that the D350N substitution enhances the uptake of calcium into the active region, stabilizing the cofactor-binding architecture and thereby supporting a higher maximum reaction velocity. The team confirmed the functional importance of both positions through site-directed mutagenesis, individually altering the relevant residues and measuring the resulting changes in activity and substrate affinity.

Together, the structural and biochemical data point to a clean division of labor between the two mutations. The change in the position of arginine 352, set in motion by the D350N substitution’s effect on the loop, accounts for the reduced Michaelis constant, because removing the steric obstruction allows glucose to bind more readily. The improved calcium retention, meanwhile, explains the enhanced maximum velocity, because a properly loaded active site can execute catalysis at a faster rate. It is a textbook example of how two mutations at different locations can produce complementary improvements through distinct structural mechanisms, and it illustrates why crystallography remains indispensable for interpreting the outcomes of directed evolution experiments.

The broader significance of the work lies in its implications for enzyme engineering and bioelectronics. Hyperthermophilic enzymes are prized for their robustness, but their often modest catalytic rates have limited their commercial deployment. By showing precisely which structural features throttle the activity of PaeASD, the study provides a rational template for future optimization, not only of this enzyme but potentially of other PQQ-dependent dehydrogenases used in glucose sensors and biofuel cells. Enzyme-based glucose sensors, in particular, represent a large and growing market, and cofactors like PQQ offer advantages over oxygen-dependent oxidases, including the possibility of wiring enzymes directly to electrodes for efficient electron transfer.

The research also underscores the value of extremophiles as sources of industrial biocatalysts. Pyrobaculum aerophilum, the archaeon from which PaeASD was originally isolated, grows optimally at temperatures near the boiling point of water, and the enzymes it produces have evolved to maintain stable structures under conditions that would denature most proteins from conventional organisms. Combining that innate stability with laboratory-engineered improvements in catalytic efficiency, as the Fukui-led team has now demonstrated, may finally allow these rugged biocatalysts to meet the performance thresholds demanded by real-world devices.

The study, funded in part by the Japan Society for the Promotion of Science and the Public Utility Foundation for the Vitamin & Biofactor Society, was published open access under a Creative Commons license, making the structural data freely available to researchers worldwide. As bioelectronic devices move from laboratory prototypes toward commercial products, the ability to see, atom by atom, how a single loop movement and a retained calcium ion can multiply an enzyme’s output offers both a practical roadmap and a vivid reminder that in molecular biology, the smallest changes often carry the largest consequences.

Subject of Research: Structural basis of enhanced catalytic activity in an engineered hyperthermophilic PQQ-dependent aldose sugar dehydrogenase

Article Title: Crystal structure of an activity-enhanced hyperthermophilic quinoprotein aldose sugar dehydrogenase

Article References: Maeno, M., Sakuraba, H., Yoneda, K., Ohshima, T., Suye, S.-I., & Satomura, T. (2026). Crystal structure of an activity-enhanced hyperthermophilic quinoprotein aldose sugar dehydrogenase. Applied Microbiology and Biotechnology. https://doi.org/10.1007/s00253-026-14026-2

Image Credits: AI Generated

DOI: 10.1007/s00253-026-14026-2

Keywords: PQQ-dependent dehydrogenase, hyperthermophilic enzyme, directed evolution, crystal structure, Pyrobaculum aerophilum, glucose oxidation, calcium ion, Michaelis constant, bioelectronics, biosensors, enzyme engineering, biocatalysis